Lv2
170 积分 2023-04-19 加入
LRRK2-targeting antisense oligonucleotide in Parkinson’s disease: a phase 1 randomized controlled trial
22小时前
待确认
Development of potent humanized TNFα inhibitory nanobodies for therapeutic applications in TNFα-mediated diseases
14天前
已完结
Amphiregulin and Fibrosis: Existing Evidence and Future Directions
18天前
已关闭
RIPK2 inhibitors for disease therapy: Current status and perspectives
28天前
已完结
Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis
30天前
已完结
特发性肺纤维化诊断和治疗中国专家共识
30天前
已完结
The potent and selective RIPK2 inhibitor BI 706039 improves intestinal inflammation in the TRUC mouse model of inflammatory bowel disease
1个月前
已完结
Simultaneous substrate and ubiquitin modification recognition by bispecific antibodies enables detection of ubiquitinated RIP1 and RIP2
1个月前
已完结
Receptor Interacting Ser/Thr-Protein Kinase 2 as a New Therapeutic Target
1个月前
已完结
Efficacy and safety of monlunabant in adults with obesity and metabolic syndrome: a double-blind, randomised, placebo-controlled, phase 2a trial
1个月前
已完结
皖公网安备34019202002308
